Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Post Marketing Surveillance on Safety Evaluation of REVLIMID® (Lenalidomide) Treatment of Myelodysplastic Syndromes Associated With a Deletion 5q or Mantle Cell Lymphoma in Korea

Next Previous
Trial Profile

Post Marketing Surveillance on Safety Evaluation of REVLIMID® (Lenalidomide) Treatment of Myelodysplastic Syndromes Associated With a Deletion 5q or Mantle Cell Lymphoma in Korea

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary) ; Rituximab
  • Indications Follicular lymphoma; Mantle-cell lymphoma; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Acronyms RevlimidPMS
  • Sponsors Celgene Corporation

Most Recent Events

  • 04 Jan 2024 Status changed from active, no longer recruiting to completed.
  • 20 Nov 2023 Planned End Date changed from 1 Jun 2022 to 6 Dec 2023.
  • 20 Nov 2023 Planned primary completion date changed from 1 Jun 2022 to 6 Dec 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top